Intraperitoneal Chemotherapy in Advanced Ovarian Cancer Improves Survival, But Is Underused

Use of intraperitoneal chemotherapy, along with intravenous chemotherapy, improves survival in some women with advanced ovarian cancer, but its use...

NCI Initiative to Speed Development of Childhood Cancer Therapies

NCI has awarded grants to five research teams to participate in its Pediatric Preclinical Testing Consortium, which is intended to...

FDA Approves Rolapitant to Prevent Nausea and Vomiting from Chemotherapy

The FDA has approved rolapitant to prevent chemotherapy-induced nausea and vomiting. Source link

NCI Releases Budget Proposal for Fiscal Year 2017

The NCI Annual Plan and Budget Proposal for Fiscal Year 2017 provides an overview of NCI’s priorities and key initiatives...

For Some Children with Cancer, Genomic Information May Help Guide Treatment Decisions

Genomic methods, such as DNA sequencing, may help doctors manage the treatment of children and young adults with cancer. Source...

CPTAC, the Complementary Sibling of TCGA: An Interview with Dr. Henry Rodriguez about NCI’s Proteomics Program

Dr. Henry Rodriguez explains the goals and future directions of CPTAC, a collaborative consortium of institutions and investigators who study...

Cancer Trends: Influencing Care and Research Priorities

Many of the trends being seen in cancer are changing how we view cancer and how we address it, from...

"Fine Tuning" Engineered T Cells May Extend Immunotherapy Approach to More Cancer Types

Engineering immune cells to have a decreased affinity for their targets on cancer cells may not weaken their efficacy but...

Persistence of Genetic Mutations after Chemotherapy Linked to Poor Outcomes in Some Patients with AML

The persistence of genetic mutations in some patients with acute myeloid leukemia may allow physicians to better classify their risk...